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S U M M A R Y
Although almost a century has gone by since its ﬁrst description in the country, Turkey has not been able
to eradicate brucellosis, which remains a major public health problem. In this review, we give an
overview of the epidemiological and epizootic status of brucellosis in Turkey. Although little readily
accessible data concerning the epidemiology of brucellosis in Turkey are available, the limited ofﬁcial
and published data were analyzed. Despite being endemic in Turkey, brucellosis remains under-
diagnosed and under-reported. Adherence to traditional farming practices and lifestyles and the
consumption of fresh dairy produce contribute to the high incidence of brucellosis. The successful
implementation of a national brucellosis control program requires strong political will, good funding,
and collaboration, especially between the public health and veterinary sectors. Primary healthcare
workers should always keep the symptoms of acute and chronic brucellosis in mind when treating
patients.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The World Health Organization (WHO) considers that brucel-
losis is a zoonotic infection with a worldwide impact, contributing
to signiﬁcant health and economic problems.1 Although almost a
century has gone by since its ﬁrst description in the country,
Turkey has not been able to eradicate the disease and the
population is at great risk of acquiring brucellosis.2 Nearly every
case of human brucellosis has an animal origin and, therefore,
control is primarily a veterinary problem.3 Other than direct
contact with infected animals, the disease is also foodborne; food
habits are very difﬁcult to change, which will assure many future
cases of foodborne disease. The diagnosis of human brucellosis is
not difﬁcult if the level of suspicion is high and the presentation is
typical, but the varied and sometimes misleading manifestations of
localized, sub-acute, or chronic infection mean that cases may be
misdiagnosed.4–6 A safe and effective vaccine for use in man is not
yet available.
2. The organism
The genus Brucella is included in the a2 subclass of the
Proteobacteria, which encompasses a variety of plant and
animal pathogens that are characteristically associated* Corresponding author. Tel.: +90 262 303 7448.
E-mail address: yumuk@me.com (Z. Yumuk).
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and the Rhizobiaciae), and also includes intracellular pathogens
of mammals (Brucella, Bartonella, Ochrobactrum, and the
rickettsiae).7
The ofﬁcial classiﬁcation of Brucella is based solely on
phenotypic characterization using a range of bacteriological and
biochemical tests.8 Under the classical nomenclature, six species
were initially differentiated on the basis of their preferred host,
their susceptibility to lysis by a number of speciﬁc phages, and the
pattern of oxidation of a variety of carbohydrate and amino acid
substrates. The number of species has increased to 10 over recent
years as several new Brucella strains have been isolated, ﬁrst from
marine mammals, then from voles, rodents, and from an infected
human breast implant.9–11
Brucella melitensis, Brucella abortus, and Brucella suis are the
three species generally associated with human disease. Rare cases
of human infection with Brucella canis have been reported, while
human cases of Brucella ovis and Brucella neotomae infection have
not been reported. Little is known about the capacity of the new
Brucella species to cause infection. One possible laboratory-
acquired infection with a marine mammal isolate has been
reported,12 and one speciﬁc sequence type (ST27) has been
associated with three human infections in Peru and New
Zealand.13 Interestingly, the patients had had no contact with
marine mammals; however contact with raw ﬁsh was a common
feature of the three cases. Recently, there has been a report of B.
melitensis bv2 found in catﬁsh in Egypt, suggesting that ﬁsh may
constitute a novel source of infection.14ses. Published by Elsevier Ltd. All rights reserved.
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Most Brucella species are highly virulent, causing an acute
infection in both their natural and accidental hosts. The bacterium
has a reputation for being a ‘stealth pathogen’ that can infect
without inducing a massive inﬂammatory response. Its ability to
survive and multiply in host cells, such as macrophages in the
reticuloendothelial system and trophoblasts in the placenta, is a
key aspect of its virulence. Over the last 20 years, considerable
advances have been made in understanding the genetics and cell
biology of Brucella virulence, and these have been reviewed
recently.15–17 It enters cells via lipid rafts, which help in the
avoidance of defense mechanisms. The bacterium’s lipopolysac-
charide and a periplasmic cyclic b-glucan are essential for the ﬁrst
steps in the establishment of an intracellular replication niche, in
which Brucella survives and multiplies. Acidiﬁcation of the
phagosome induces the expression of several virulence factors
including the VirB type IV secretion system. The VirB system is
thought to translocate effector proteins into the host cell, which
modulate host cell biology to create the intracellular replication
niche.18 Brucella creates its replication vacuole by capturing
membrane vesicles at endoplasmic reticulum exit sites, a tactic
used by some other intracellular pathogens, including Legionella.
4. Brucellosis in animals and man
The major symptom of brucellosis in animals is infectious
abortion as a result of the bacteria invading the placenta and the
fetus. The bacteria may grow to very high density and the aborted
placenta and fetus may contain up to 1010 infectious bacteria per
gram of tissue or ﬂuid. Infected animals effectively remain carriers
for the rest of their lives, even though they may abort only once.
During this time they excrete large numbers of organisms in their
milk, as well as in the products of subsequent, apparently normal,
parturitions. Infection in man can therefore occur by the ingestion
of raw milk or milk products such as cream and cheese, or by the
handling of infected animals, especially around the time of
parturition. Pasteurization effectively protects the urban popula-
tion in most regions of Turkey, but stockowners and their families
often drink raw milk and are at risk from direct contact with
infected animals.
Humans are susceptible to infection, which often manifests
initially as an acute febrile illness. This illness has various names
including Malta fever, Mediterranean fever, and undulant fever. In
the Turkish community, the disease has several other names such
as ‘peynir hastaligi’, ‘mal hastaligi’, and ‘koyun hastaligi’. The
disease in man is manifested through a diverse range of clinical
symptoms and signs, the most important of which is undulant
fever.19,20 A substantial proportion of patients present with
splenomegaly and/or hepatomegaly. When the disease becomes
chronic, a very wide range of pathological conditions may occur,
affecting nearly all organs in the body, including spondylitis,
endocarditis, and meningoencephalitis (reviewed by Young6 and
Pappas et al.19). Neurological complications also occur. The
recommended treatment is a long course (at least 6 weeks) of
combinations of antibiotics, notably rifampin plus tetracycline or
gentamicin or (parenteral) streptomycin.21,22 Antibiotic resistance
is not a problem encountered with Brucella, and testing isolates for
antibiotic sensitivity is discouraged due to the risks of laboratory-
acquired infections.
5. Brucellosis in Turkey
The ﬁrst documented case of laboratory-conﬁrmed brucellosis
in Turkey was in 1915,23 although it is generally thought that
Florence Nightingale contracted brucellosis in Turkey during theCrimean War.5 The ﬁrst cases of B. abortus infection were
diagnosed in 1932.24 B. melitensis probably accounts for the
majority of cases of brucellosis in humans in Turkey, with
B. abortus the second most frequent. In 1949, Golem isolated 22
Brucella strains from clinically ill brucellosis patients; 21 were
B. melitensis and only one was B. abortus.25 In 1970 the reported
incidence of brucellosis was low, with only 37 declared cases. By
2004, the reported incidence had risen to over 18 000 cases, or
256.7 cases per million. As discussed by Buzgan et al.,26 this
dramatic increase most certainly reﬂects improvements in
healthcare, diagnosis, and reporting, not an increase in the real
incidence of the disease. There is no information concerning the
incidence of B. suis in Turkey. Pig farming is not common (the
population is predominantly Muslim), and press reports suggest
that the existing commercial farms are being closed by the
government due to ‘hygiene problems’ (http://news.bbc.co.uk/2/
hi/programmes/from_our_own_correspondent/7368020.stm).
Hunting wild swine is a popular sport; feral pigs and wild boar can
carry B. suis bv1, bv2, and bv3, however it appears that bv2 has only
low virulence in man.27 The incidence of Brucella in wild swine in
Turkey merits investigation. B. canis carried by dogs can
occasionally be passed on to man. Istanbulluoglu and Diker28
studied 134 healthy pet and stray dog serum samples on a random
basis for B. canis antibodies and found that the reactor rate among
the stray dogs was 12% compared to a reactor rate of 3.5% for the
pet dogs. Although no culture-positive cases have been reported,
studies have reported serological evidence of B. canis infection in
man; Diker et al.29 randomly collected serum samples from 123
individuals and found seropositivity in two. Koksal et al.30
collected serum samples from 514 patients with suspected
brucellosis and found B. canis seropositivity in 43. There is very
little information about the incidence of B. ovis.
6. Geopolitical situation
Turkey occupies a unique geographic, cultural, and economic
position at the cross-roads between Europe and Asia. It is bounded
by the Black Sea in the north, the Mediterranean Sea in the south,
and the Aegean Sea in the west. It shares land boundaries with
Greece and Bulgaria in the northwest, Georgia, Armenia and
Azerbaijan in the northeast, Iran in the east, and Iraq and Syria in
the southeast. Conditions in Turkey are favorable for the raising of
livestock, but total numbers have been slowly declining over the
last decade. In spite of the generally decreasing numbers, total
animal production ﬁgures have remained constant, indicating an
improved productivity per animal. In 2009 there were over 26
million sheep, nearly 11 million cattle, almost 6.5 million goats,
and 217 million poultry in the country (http://www.turkstat.-
gov.tr/VeriBilgi.do?tb_id=46&ust_id=13). The geographic situation
of Turkey is always a risk factor for the dissemination of contagious
diseases, mainly from the eastern and southeastern neighbors.31
Brucellosis is endemic in all of the countries surrounding Turkey. In
Iran, the prevalence of brucellosis among sheep/goats was 10.2%
and among cows was 17.5% in the 1990s.32 Human brucellosis is a
serious public health problem in Iran, with 238.6 cases per
million.19,33 In Iraq, the prevalence among sheep and goats was
15% and among investigated cattle was 3%, with 278.4 human
cases per million. Syria has the world’s highest reported incidence
of human brucellosis, with 1603.4 cases per million.34 The
prevalence of bovine brucellosis was about 3.1% and of sheep
brucellosis was about 3.0% in the 1990s. The situation in Syria is
rapidly worsening.19 Illegal animal movement through the borders
to Turkey has been minimized in recent years by changes in the
relevant Articles of the Law 3285 in 2001. With these changes, the
penalties for illegal animal movements and smugglers have
increased (http://www.fao.org/ag/AGAinfo/commissions/en/
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establish collaboration in the eradication and prevention of
brucellosis between all countries in the region, as discussed by
Refai.32 The recent events of the ‘Arab Spring’ and the political and
social unrest in the countries bordering Turkey, including Syria,
underline this problem.
7. Clinical aspects of human brucellosis in Turkey
Turkey is a relatively rich country with a well developed health
system. This means that clinicians have both the medical and
scientiﬁc skills and the medical infrastructure to investigate
human brucellosis. Over the last decade, there have been several
studies including large numbers of cases. Recently Buzgan et al.26
made a retrospective evaluation of 1028 cases that occurred in the
Lake Van region between 1998 and 2007. Cases were either
associated with ingestion of unpasteurized dairy products or
contact with livestock, reﬂecting the rural nature of the region.
Interestingly there were two seasonal peaks, following traditional
periods of consumption of fresh cheese. Incidence was highest in
younger patients (54% aged between 14 and 34 years), perhaps
reﬂecting the traditional role of children in raising livestock. It may
also reﬂect the acquisition of immunity to a second infection in the
population with age. The large number of cases encountered has
allowed clinicians to study the different pathologies and associated
complications. Focal involvement was seen in 36% of cases, with
osteoarticular involvement being the most common complication,
seen in around 25% of patients. Involvement of the central nervous
system (CNS), genitourinary tract, and liver were also common.
Diagnosis was made from positive serology and, when possible,
bacteriological culture. Many studies in Turkey have concentrated
on speciﬁc complications such as neurobrucellosis, epididymo-
orchitis, and endocarditis. A review of the recent literature is
presented in Table 1.35–52
In animals, brucellosis is associated with infectious abortion;
however the situation in humans is not clear. There were 17
pregnant women among the 1029 patients in the study of Buzgan
et al.26, and none of them had any complications or miscarriage.
Kurdoglu et al.45 reported that in 29 cases of brucellosis during
pregnancy, there were eight incidents of spontaneous abortion or
intrauterine fetal death and two preterm deliveries. Again, there
was a very strong correlation with the consumption of unpasteur-
ized cheese and close contact with livestock. The patients were
generally of low socioeconomic class and of low educational level,
suggesting that greater efforts should be made to educate this
population about the risks of brucellosis. Cebesoy et al.53 reported
a 21-year-old pregnant woman who had a Brucella-related lumbar
vertebral fracture in the ﬁrst trimester of her pregnancy.
Ceftriaxone 1 g twice daily and rifampin 600 mg daily were
prescribed for 6 months. The delivery occurred at 39 weeks of
gestation by cesarean section with no complications for the mother
or baby.
8. Epidemiology
Until the 1980s, cases of human brucellosis were rarely
registered in Turkey. For example, between 1930 and 1980, fewer
than 2000 cases were registered. During the period 1980–2005, a
total of 189 226 cases of human brucellosis were reported
ofﬁcially; about 90 000 of these were registered between 2000 and
2005 (approximately 15 000 cases per year). This, however, does
not reﬂect the actual numbers, since the estimated ratio of
registered to unregistered cases is around 1:30.54 Examples of the
incidence of cases in various regions of Turkey are presented below
and in Figure 1.23–25,52,55–64The ﬁrst laboratory-conﬁrmed brucellosis case in Turkey was
reported in 1915.23When the Turkish literature from 1915 to 1963
were reviewed, it was found that in 48 years, 11 621 individuals
were tested for brucellosis by agglutination test and of these
approximately 9% were found to be positive.23 In 1937, Celik
studied 1157 individuals and found brucellosis in 2.6%.24 In 1943,
Golem studied 1154 individuals and found brucellosis in 5.9%.55 In
1957, Akyay and Gursel studied 2424 individuals and 203 abattoir
workers in Eskisehir City in Central Turkey, and found brucellosis
in 4.3% and 23.1%, respectively.65
More recently, a large-scale seroepidemiological survey was
conducted in different parts of Turkey. In 1990, Cetin et al. studied
58 707 healthy individuals and 3734 abattoir workers in different
major cities throughout Turkey (Istanbul, Ankara, Konya, Antalya,
Diyarbakır, I˙zmir, Sivas, Erzurum, and Bursa) and found active
brucellosis in 1.8% and 6%, respectively.59 The highest level of
seroprevalence observed among healthy individuals was 3.6% in
Diyarbakır, which is in eastern Turkey. Cetinkaya et al. investigated
1850 individuals in rural areas of Anatolia and found brucellosis in
3.4%.66,67 In another recent study, Kose et al. conducted a
seroepidemiological study on brucellosis in humans in rural and
urban populations in different provinces of Turkey.68 They tested
832 apparently healthy adults using Rose Bengal and standard
agglutination tests and found an overall seroprevalence of 3.0%.
The seroprevalence in communities in the provinces of southeast
Turkey was lower than in the provinces in the west, and the
authors attributed this to the vaccination of livestock in the year
preceding the survey. In other studies in Turkish cities between
1991 and 2005, seroprevalences using Rose Bengal were reported
for the cities of Afyon (15.7%), Malatya (2.9%), Denizli (6.5%),
Kayseri (3.4%), Bolu (1.3%), and Van (26.7%).66–71
Brucellosis was once believed to be uncommon in children, but
it is now recognized that people of all ages are susceptible.
Amongst the 1028 cases in Van in eastern Turkey reviewed by
Buzgan et al., 3.6% were aged 3–12 years.26 Tanir et al.
retrospectively reviewed 90 children with brucellosis at a public
children’s hospital in the Turkish capital city Ankara.72 The
diagnosis of brucellosis was based on clinical signs, serum
agglutination, and blood culture. Blood cultures were performed
in 37 brucellosis patients (41.1%) and were positive in 16 (17.8%) of
them. Fifty-two patients (57.8%) were from rural areas and 38
(42.2%) from urban areas of Turkey. In 64 children (71.1%), the
mode of transmission was consumption of fresh cheese. The
possible source of transmission was not revealed in 26 children.
Parents of 41 children (45.6%) worked on farms. There was a
positive family history of brucellosis in 14 (15.6%) children. Fifteen
(16.6%) children were hospitalized. The most common presenta-
tion was arthralgia with fever. The most frequently involved joint
with arthralgia was the knee joint. Neurobrucellosis were seen in
two (2.2%) and was successfully treated with co-trimoxazole plus
rifampin and gentamicin combination or doxycycline plus rifam-
pin and gentamicin. Only six patients were readmitted to hospital
because of relapse.
9. Mode of transmission
Brucellosis is a zoonosis and, with few exceptions, infections in
humans result from direct or indirect contact with animal sources.
As highlighted above, the main source of infection for the general
population is dairy produce prepared from infected milk; B.
melitensis presents the greatest hazard (http://www.tarim.gov.tr/
Files/Files/e_kutuphane/1fao-dairy_Eng_Final_Report.pdf). The
milk of infected sheep and goats may contain large numbers of viable
organisms, which become concentrated in products such as soft
cheese.73 Indeed, soft cheese has been recognized as one of the major
vehicles of infection in Turkey.43 In Turkey, a great part of goat milk is
Table 1
A review of the recent literature on the clinical aspects of human brucellosis in Turkey
Publication type Reference Summary
Review 35 Between 1989 and 1998, brucellosis was diagnosed in 480 patients, of whom 67.1% had the acute
form, 25.2% had the subacute form, 5% had the chronic form, and 2.7% were asymptomatic. The
clinical form is diagnosed by positive serology. It was documented more frequently in farmers,
abattoir workers, and veterinarians. In the series, 27.7% of patients had complications: CNS
involvement was observed in 6.5% of the patients.
36 A prospective study evaluating 138 patients with active brucellosis between 2000 and 2002.
Osteoarticular involvement was found in 64 patients (46.4%). Ten (7.5%) patients had
orchiepididymitis. Meningitis, pulmonary involvement, endocarditis, and hepatitis were found in
ﬁve (3.6%), three (2.1%), two (1.5%) and one (0.7%) patients, respectively.
37 A retrospective study; 480 brucellosis cases were included. Cultures were positive in 45% of cases
and all strains were identiﬁed as B. melitensis. Various treatment regimens were given to patients;
relapses occurred in 5.2% of the patients using doxycycline– streptomycin combination. The relapse
rate was found to be higher in the tetracycline– streptomycin group than in the doxycycline–
streptomycin and doxycycline–rifampin groups.
38 A prospective study; 54 acute bacteremic brucellosis cases were included. The majority of patients
(76%) were from rural Anatolia. B. melitensis biovars were more common than B. abortus (83% vs.
17%). Fever and arthralgia were the most common symptoms. The number of patients with back
pain and arthralgia was higher in the B. abortus-infected group.
Childhood brucellosis 39 A retrospective study with 103 brucellosis cases from eastern Turkey. Ages ranged from 20 months
to 16 years. The period between onset of symptoms and admission to hospital ranged from 2 days to
3 years. A positive family history for brucellosis was noted in 13.5% of patients.
Epididymo-orchitis 40 Epididymo-orchitis as a complication of brucellosis in 17 patients. Although the SAT was positive
for all patients, Brucella were isolated from the blood cultures of 10 (58.8%). Nine were B. melitensis
and one was B. abortus.
Neurobrucellosis 41 Between 1999 and 2004, brucellosis was diagnosed in 305 patients, of whom 6.6% had
neurobrucellosis. Patients were treated medically with doxycycline plus rifampin plus ceftriaxone
combination and a complete resolution was achieved in all.
42 41 Brucella isolates obtained between 2001 and 2002 from blood and CSF cultures of adult patients
with brucellosis at a public hospital in Central Turkey, Ankara City. Two isolates from the blood
culture were identiﬁed as B. melitensis bv1 and the other 39 strains were B. melitensis bv3.
43 Review of 452 cases of spinal brucellosis from the Turkish literature (1989–2004). Brucella culture
was performed for 26.7% patients of whom 73.5% were culture-positive (34 B. melitensis and ﬁve
B. abortus).
44 Case of basilar artery aneurysm and subarachnoid hemorrhage due to brucellosis in a 20-year-old
male. The patient was cured medically with rifampin and doxycycline combination; no surgical
intervention was needed.
Pregnancy and brucellosis 26,45 The incidence of brucellosis in pregnancy was found to be 1.7%. Medical records of 21 pregnant
women were reviewed retrospectively. Spontaneous abortion, intrauterine fetal death, and preterm
delivery rates were 24.14%, 3.45%, and 6.9%, respectively. Consumption of unpasteurized dairy
products had occurred in 92.3% of the cases.
Hematological localization 46 Retrospective review showing that pancytopenia is a common feature of brucellosis. The records of
202 patients with brucellosis were evaluated retrospectively; 30 patients with pancytopenia were
identiﬁed.
47 Thrombotic microangiopathy as a rare complication of brucellosis and associated with brucellosis
that was treated with plasmapheresis plus antimicrobial therapy.
48 Two cases with fever and pancytopenia, diagnosed as simultaneous acute lymphoblastic leukemia
and brucellosis. Anti-leukemia therapy and brucellosis treatment were administered
simultaneously. One of the cases later died due to a leukemia relapse.
Blood transfusion 49 Contamination of two newborns by exchange transfusions, however the newborns did not develop
brucellosis.
Brucellosis in Turkish immigrants 50 Two cases of B. abortus infection in Turkish immigrants in Denmark. One of the cases was a pregnant
woman. No cultures were done from the aborted fetus. The diagnosis was ﬁnally established by
means of blood cultures, which were performed because of fever of unknown origin. In both cases,
the source of the brucellosis was found to be unpasteurized dairy products from Turkey.
Antimicrobial susceptibility 51 Fifty blood isolates were tested with tetracycline, gentamicin, streptomycin, ceftriaxone,
ciproﬂoxacin, levoﬂoxacin, oﬂoxacin, and rifampin. All of the clinical isolates were B. melitensis bv3.
All antibiotics were found to be effective in vitro against B. melitensis, however the MIC values of
ceftriaxone and streptomycin were found to be high.
Survey 1991 52 The national survey showed 1.83% prevalence for B. melitensis (from 11 122 blood serum samples)
and 1.01% prevalence for B. abortus (from 7812 blood serum samples).
CNS, central nervous system; SAT, standard agglutination test; CSF, cerebrospinal ﬂuid; MIC, minimum inhibitory concentration.
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milk butter producing locality in Turkey. In the provinces of
Gaziantep and Sanliurfa, goat milk butter is melted together with
sheep milk butter and supplied to the market. In the city of
Kahramanmaras in the Mediterranean Region, ice cream is made
exclusively from goat milk and is quite popular in many large cities
of Turkey.74
In Turkey, the producers quite often bring their milk products
such as cheese, butter, and yogurt to the markets in the small cities
and towns75 (http://ekutup.dpt.gov.tr/gida/oik644.pdf). The other
practice for the marketing of milk is through merchants collectingand processing the milk. Such small-scale cottage type operations
are common, particularly in eastern Turkey. The operators often set
up their units in the villages and have strong relationships with the
producers. They usually form contracts and pay in advance for the
season’s production. The hygiene conditions of milk processing are
not always satisfactory and as a consequence the quality of the
products is subject to wide variation. Tekinsen and Celik76
described the main problems encountered with the manufacturing
of white pickled cheese in Turkey. They compared the manufactur-
ing techniques with those in developed countries, concluding that
major improvements regarding hygiene are needed.
2000s90s80s70s60s50s40s1930s
0
10
20
30
40
Human
Sheep
Bovine
Years
S
e
ro
p
o
s
it
iv
e
 (
%
)
Figure 1. Seroprevalence of human and animal brucellosis in Turkey, 1930s–
2000s.23–25,52,55–64.
Z. Yumuk, D. O’Callaghan / International Journal of Infectious Diseases 16 (2012) e228–e235e232Direct contact with livestock is a well documented source of
infection. Infection may occur through cuts and abrasions on the
skin, via the conjunctiva, and by inhalation. These routes of
infection are important for farmers, veterinarians, and butchers,
who are all at increased risk of infection through their contact with
animals and animal products. In 1971, Ogutman carried out a
seroepidemiological study on 2626 individuals in Erzurum, a city
in eastern Turkey.77 Among these individuals there were 385 (1.5%
positive) people who had been in close contact with animals but
with no evidence of clinical brucellosis, 616 (1.3% positive)
individuals who had not been in contact with animals and had
no evidence of clinical brucellosis, 283 (18% positive) individuals
who had been in close contact with meat or meat products but
with no clinical evidence of brucellosis, 505 (7.4% positive)
individuals who had not been in contact with animals or meat
or meat products with brucellosis but who had a high consumption
of milk or milk products, 337 (11.7% positive) workers who
slaughtered cattle, and 500 (39.9% positive) workers who
slaughtered sheep. The overall incidence of active brucellosis
was 13.3%. The highest incidence was found in abattoir workers. A
seroprevalence study was carried out on occupational risk groups
consisting of veterinarians and veterinary assistants, slaughter-
house workers, and controls in Kocaeli, a city in northwest Turkey.
Serum samples of 242 individuals (104 in the occupation risk
groups and 138 controls) were evaluated using Rose Bengal, ELISA,
and standard agglutination tests. The ELISA results showed a
signiﬁcantly higher brucellosis seroprevalence of 4.8% in the risk
groups compared to seroprevalence of 0% in the control group. All
positive samples were from vets (Yumuk Z, Cigdem C, Isik C, Ocak Z,
unpublished data).Table 2
A review of the literature on the epidemiological aspects of animal brucellosis in Turk
Year Summary 
1960–1970 A study on sheep herds performed at a state farm
1965–1966 In sheep breeding farm in Merino, 9% of animals w
1968–1969 The seroprevalence of brucellosis in cattle and she
respectively.
1990 Prevalence in sheep and goats was 2.8% (from 7361
was 1.2% (from 5701 blood serum samples).
1991 The national survey showed 1.83% prevalence for B
and 1.01% prevalence for B. abortus (from 7812 bl
1992 A seroepidemiological study on 3580 cattle and 44
areas of Turkey showed positivity against brucello
1998–1999 A seroepidemiological study gave an overall rate o
and sheep, ranging from nil to 11.5% in three diffeThe highly infectious nature of Brucella makes laboratory-
acquired brucellosis a common problem in diagnostic and research
laboratories. At the Ankara Numune Education and Research
Hospital, when 48 healthcare workers with a professional risk of
infection were questioned, 12 were found to have had brucellosis,
giving an infection risk of 8% per employee year.78 The main
reasons for these infections were the absence of appropriate safety
equipment and poor laboratory practices, which have all been
improved since this report.
10. Animal brucellosis
Reviewing the Turkish literature from 1932 to 1963 shows that
bovine, ovine, and caprine brucellosis was a serious problem in
both state and private farms, with up to 20% of animals showing
positive serological reactions.23–25 A serological study mainly on
sheep and goats in state farms was conducted on 198 116 blood
serum samples from 1952 to 1963 and showed 2.6% reactors.23 The
clear relationship between infected animals and humans was
shown in a report in 1957; a herd in Eskisehir suffering acute
brucellosis showed 11% reactors, with 23% of workers testing
positive.65
Iyisan et al. published the data of surveys that were performed
by the Ministry of Agriculture, Forestry and Rural Affairs between
1989 and 1999.52 In 1989 the overall rate of positive reactors in
cattle was 3.56% and of positive reactors among sheep was 1.26%,
with rates in different provinces ranging from nil to 10%. The
details are described in Table 2.52,58,64
11. Animal disease control in Turkey
The ﬁrst step towards a national control program came after
contagious abortion was recognized along with tuberculosis as a
serious cause of economic losses with legalization in 1937.25 The
Ministry of Agriculture and Rural Affairs is the authority
responsible for animal disease control in Turkey. The framework
for all prevention, protection, and eradication of animal disease is
set out in The Law of Animal Health Control No. 3285 (AHCL) and
The Guide of Animal Health Control No. 3285 (AHCG). The
obligations concerning notiﬁcation of the diseases are laid down by
Article 9–11 of AHCL and Article 25–35 of AHCG. Brucellosis
control started in the early 1950s with an unsuccessful ‘test and
slaughter’ program and a more successful vaccination campaign in
the 1960s.
A control and eradication program for brucellosis (B. melitensis)
in sheep and goats started mainly in the state farms in 1952. The
animals were tested serologically and reactors were slaughtered
leaving the non-reactors in the herd. With hindsight, it is clear that
this was not the correct approach considering the high incidence of
brucellosis in the herds, and a program of mass vaccination wouldey
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prevalence of brucellosis in animals is below 1%, short-term
eradication of the disease by test and slaughter of seropositives
may be most economical, but in Turkey the prevalence of
brucellosis in herds is as high as 10%. Common pastures and
watering areas, uncontrolled movement and importation of
animals, and other practices that contribute to transmission are
difﬁcult to manage. Other limitations include the logistics of
performing tests, the refusal of livestock owners to cooperate, and
the lack of sufﬁcient funds for program administration.
Two live vaccine strains have proven efﬁcacy against animal
brucellosis: B. abortus strain 19 (S19) for bovine brucellosis and B.
melitensis Rev1 for caprine and ovine brucellosis. Vaccination of
calves with S19 was made compulsory on state farms in Turkey in
1960.80 Later some private farms were added to the campaign. A
national brucellosis control and eradication project was implemen-
ted on a regional basis in 1983 in which all the female calves between
4 and 8 months old were to be vaccinated with S19.52 Over 26 years,
a total of about 7 million calves were vaccinated. In 1991, the Thrace
region was selected as a pilot region for an adult vaccination
program in which 124 000 heifers were vaccinated with a reduced
dose of S19.62 This was extended to all heifers from infected herds,
and by the end of 1995 over half a million animals had been
vaccinated. As shown in Figure 1, vaccination had a major effect on
brucellosis disease with a low level of seropositivity found for both
human and animal brucellosis in the 1960s–1970s and 2000s.
The ﬁrst attempts to vaccinate with Rev1 in Turkey started in
1968.81 A heavily infected state sheep farm, with 15% reactor and 5%
abortion rates, was selected. All adult sheep and goats, and lambs
and kids aged between 4 and 6 months were vaccinated 1 month
before the breeding season with a full dose Rev1 (2  109). The
results were very promising with ﬁve-times fewer abortions and six-
times fewer reactors in the subsequent season. After these results, all
the sheep, lambs, goats, and kids were vaccinated with Rev1 vaccine
on the state farms in the following year and some private farms were
also added to the campaign. On the state farms, Brucella-related
abortion fell to 7.3% in 1968 and to 0.57% in 1969, with no abortion
reported in the following years.64 The lambing rate also increased,
reaching 15–20% on these farms, showing how successful the
vaccination programs were. Vaccination on private farms started in
1974, and 1.5 million sheep and goats were vaccinated in the ﬁrst 5
years with good results. In 1983, all lambs and kids between 3 and 8
months old were vaccinated with Rev1, and over 26 years, a total of
about 64 million small ruminants were vaccinated.52 In the adult
vaccination program, 840 000 adult female sheep and goats were
vaccinated with a reduced dose of Rev1 vaccine in the Thrace regions
in 1991, with another 4 million adult female sheep and goats
vaccinated by the end of 1995.62 At the beginning of the vaccination
program, the percent of seropositivity decreased dramatically in
animal brucellosis, however in the following years the percentage
increased gradually (Figure 1).
Recently, following the European Community Council direc-
tives on animal health problems affecting intra-community trade
in bovine and ovine animals, a new national brucellosis control and
eradication project was begun in Turkey, on April 3, 2009. Cattle
and small ruminants have been classiﬁed into four groups which
are considered to be easy to manage in the eradication of the
disease (http://www.kkgm.gov.tr/yonetmelik/bruselloz_mucade-
le_yon.html).
12. Brucella vaccine and test antigens
Until the 1950s, all the Brucella agglutination test antigen and
strains were prepared and used in the different bacteriology
institutes and regional laboratories using their own, unstandard-
ized methods. Since 1950, serological studies have been carried outusing the standard antigen prepared by international methods and
standardized with the international standard serum. Brucella Rose
Bengal plate test antigen, slow tube agglutination test antigen, and
milk ring test antigen are produced by the Pendik Veterinary
Control and Research Institute. The use of common, standardized
antigens and strains is essential for an effective control and
eradication program.
13. Conclusions
Although brucellosis has been, or is close to being, eradicated
from a number of developed countries, it continues to be a major
public and animal health problem in many regions of the world.
There are numerous reasons why brucellosis remains endemic in
Turkey. These include the uncontrolled movements of livestock
herds and ﬂocks and the geopolitical situation, with endemic
brucellosis in surrounding countries, and political instability. In
Turkey, limited veterinary support services and husbandry
practices favor the spread of infection. Human cases continue to
occur because of the traditional use of raw milk products and
following close contact with infected animals. As a relatively rich
country with a good and well developed healthcare system and
good universities, Turkey offers the possibility for detailed
investigations of all aspects of the physio- and immune-pathology
of human brucellosis.
Following the initiation of the national brucellosis control and
eradication plan in 1984 there was a clear reduction in the levels of
animal and human brucellosis and it is hoped that the new plan
that was initiated in 2009 will continue to make progress. In any
disease control or eradication program, decisions have to be made
on the basis of the information available. If this information is
faulty or biased, there is a greater likelihood that incorrect
decisions will be made. The key to any program, therefore, is to
develop an efﬁcient surveillance system. At present veterinary
surveillance is still the weak point. The successful implementation
of a national brucellosis surveillance, prevention, vaccination, and
control program requires strong inter-sector collaboration, espe-
cially between the public health and veterinary sectors. In Turkey,
co-operation that already exists between the public health and
veterinary sectors needs to be continued and further strengthened.
International technical and scientiﬁc collaboration, harmonization
of surveillance and control strategies, and regulation/legislation
activities are also essential for the success of national brucellosis
programs. It also requires sustained political commitment in order
to ensure that the necessary resources, human and ﬁnancial, are
made available for the medium- and long-term. The transmission
of the disease and its incidence is also related to the intensity of the
prevention activities in the human populations. The incidence of
human brucellosis is not well deﬁned in Turkey because human
brucellosis is considerably under-reported. Mandatory laboratory-
based surveillance of communicable diseases should be incorpo-
rated into the surveillance system.
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